Represented Ansun BioPharma, Inc. in connection with its $85 million Series A Financing round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. Additional investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, and Joincap Investment. Ansun intends to use the proceeds to fund a Phase 3 clinical trial of its anti-viral medication, DAS181. Read the press release.
Ansun is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses and has two products in late stage clinical development.
The San Diego-based team representing Ansun was led by Amit Singh, and included Shoshana Zimmerman (SM) and Sonya Attal (NB). Ryan Gaglio (NB) advised on tax matters.